Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 8/20 | 0.33 |
| ▸ | GUCY1B1 | Q02153 | 8/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161087 | 0.89 | PDE5A (0.38) | PDE5AGRIN1GRIN2BGUCY1A1GUCY1B1 | |
| SCHEMBL20161165 | 0.88 | PDE5A (0.34) | PDE5AKDM4CGRIN1GRIN2BGUCY1A1 | |
| SCHEMBL24205854 | 0.88 | PDE5A (0.37) | PDE5AKDM4CGRIN1GRIN2BGUCY1A1 | |
| SCHEMBL20161090 | 0.86 | PDE5A (0.39) | PDE5AGRIN1GRIN2BGUCY1A1GUCY1B1 | |
| SCHEMBL24205968 | 0.81 | PDE5A (0.38) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL20140442 | 0.81 | ESR1 (0.41) | GRIN1GRIN2B | |
| SCHEMBL21787171 | 0.80 | GRIN1 (0.32) | PDE5AGRIN1GRIN2BTLR7 | |
| SCHEMBL20161100 | 0.78 | GRIN1 (0.35) | GRIN1GRIN2BTLR7 | |
| SCHEMBL20148909 | 0.78 | L3MBTL1 (0.41) | PDE5AGRIN1GRIN2B | |
| SCHEMBL20161258 | 0.78 | PDE5A (0.52) | PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2018111795-A2 | USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885KDM4C 4368/4885GRIN1 1566/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885KDM4C 4312/4885GRIN1 1488/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885KDM4C 4312/4885GRIN1 1488/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885KDM4C 4368/4885GRIN1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.